Key Developments: Theragenics Corp (TGX)
2.02USD
24 May 2013
$0.00 (+0.25%)
$2.01
$2.03
$2.03
$2.01
58,375
65,462
$2.15
$1.32
Latest Key Developments (Source: Significant Developments)
Lifshitz Law Firm Announces Investigation Of Theragenics Corp
Lifshitz Law Firm announced an investigation into possible breaches of fiduciary duty in connection with the receipt of a proposal from Juniper Investment Company, LLC ("Juniper") to acquire all of the Theragenics Corp outstanding common stock for $2.25 to $2.30 per share in cash. The Company has entered into an agreement ("Letter Agreement") dated May 12, 2013 to deal and negotiate exclusively with Juniper through June 11, 2013 regarding a merger transaction. Lifshitz Law Firm's investigation is focused on whether the Board of Directors of the Company is acting in the Company's shareholders' best interests in connection with the sale process. Full Article
Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By Board Of Theragenics Corp In Connection With A Going Private Proposal
Levi & Korsinsky announced that it is investigating the Board of Directors of Theragenics Corp for possible breaches of fiduciary duty and other violations of state law in connection with the receipt of a going private proposal from Juniper Investment Company, LLC. Full Article
Faruqi & Faruqi, LLP Announces Investigation of Board of Directors of Theragenics Corp
Juan Monteverde, a partner at Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, announced that it is investigating the Board of Directors of Theragenics Corp for potential breaches of fiduciary duties in connection with the receipt of a going private proposal from Juniper Investment Company, LLC. Under the terms of the proposed transaction, Theragenics` stockholders will receive between $2.25 and $2.30 for each share of Theragenics common stock they own, while Theragenics` has a reported book value of $2.66. The investigation focuses on whether Theragenics` Board of Directors breached their fiduciary duties to the Company`s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Theragenics` shareholders. Full Article
Briscoe Law Firm And Powers Taylor, LLP Investigate On Theragenics Corp
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP announced that they are investigating potential legal claims against the board of directors of Theragenics Corp related to a going private proposal from Juniper Investment Company, LLC. Under the terms of terms of the proposal, Theragenics shareholders will only receive between $2.25 to $2.30 in cash for each share of Theragenics stock owned. Full Article
Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by Board of Theragenics Corp in Connection with Going Private Proposal
Levi & Korsinsky announced that it is investigating the Board of Directors of Theragenics Corp for possible breaches of fiduciary duty and other violations of state law in connection with the receipt of a going private proposal from Juniper Investment Company, LLC. Under the terms of the transaction, Theragenics shareholders will receive between $2.25 and $2.30 for each share of Theragenics stock they own. The investigation concerns, among other things, whether the proposed consideration to be paid to Theragenics shareholders is unfair, inadequate, and substantially below the fair or inherent value of Theragenics. Theragenics has a reported book value of $2.66 for the most recent quarter. Full Article
Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By Board Of Theragenics Corp In Connection With Going Private Proposal
Levi & Korsinsky announced that it is investigating the Board of Directors of Theragenics Corp for possible breaches of fiduciary duty and other violations of state law in connection with the receipt of a going private proposal from Juniper Investment Company, LLC. The investigation concerns, among other things, whether the proposed consideration to be paid to Theragenics shareholders is unfair, inadequate, and substantially below the fair or inherent value of Theragenics. Theragenics has a reported book value of $2.66 for the most recent quarter. Full Article
Theragenics Corp Receives Proposal To Acquire All Common Stock At $2.25 To $2.30 Per Share
Theragenics Corp announced that Board of Directors has received a proposal from Juniper Investment Company, LLC ("Juniper") to acquire all of the Company`s outstanding common stock for $2.25 to $2.30 per share in cash. The Company has entered into an agreement (Letter Agreement) dated May 12, 2013 to deal and negotiate exclusively with Juniper through June 11, 2013 regarding a merger transaction. During this period, the Company has agreed not to initiate, solicit, negotiate, discuss or enter into an agreement with or provide any information to any third party with respect to any alternative business combination. The $2.25 to $2.30 per share range in the Letter Agreement reflects a negotiated increase from a $2.05 to $2.10 per share range Juniper initially proposed in its letter dated May 10, 2013 to the Company. Full Article
Theragenics Corp Signs Brachytherapy Loading Services Agreement With GE Healthcare's Oncura
Theragenics Corp announced it has signed a value-added loading services agreement with Oncura, a unit of GE Healthcare, to provide worldwide brachytherapy loading services to Oncura. Under the three-year agreement, Theragenics will load and package Oncura manufactured brachytherapy seeds in prescription loaded needles, custom strands and other configurations. Oncura`s iodine-125 brachytherapy seeds are utilized primarily in the treatment of early stage prostate cancer. This agreement provides for loading services for most Oncura sales of prescription and custom loaded brachytherapy seeds worldwide, which currently includes North America, Europe, Australia and portions of Asia. Full Article
Theragenics Corp Announces Preliminary Results Of Dutch Auction Tender Offer
Theragenics Corp announced the preliminary results of its modified Dutch Auction tender offer to purchase up to $10 million of common stock, which expired at 5:00 p.m., New York time, on July 11, 2012. Based on the preliminary count by the depositary for the tender offer, a total of 7,119,345 shares of Theragenics’ common stock were tendered properly and not withdrawn properly at or below the expected purchase price of $2.10 per share. In accordance with the terms and conditions of the offer, and based on the preliminary count by the depositary, Theragenics expects to accept for payment an aggregate of 4,761,904 shares of its common stock at a purchase price of $2.10 per share, for a total cost of approximately $10.0 million, excluding fees and expenses related to the tender offer. The 4,761,904 shares expected to be purchased in the tender offer represent approximately 13.7% of Theragenics’ currently outstanding common stock. Based on these preliminary numbers, Theragenics anticipates that following the completion of the offer, it will have approximately 29,968,000 shares outstanding. The number of shares to be purchased, the purchase price and the proration information are preliminary and subject to change. Full Article
Theragenics Corp Announces Plans to Repurchase up to $10 Million of Shares in Modified Dutch Auction Tender Offer
Theragenics Corp announced that it is commencing a modified Dutch Auction tender offer to purchase up to $10 million of its common stock. Under the terms of the tender offer, Theragenics stockholders will have the opportunity to tender some or all of their shares at a price within a range of $2.00 to $2.40 per share. Based on the number of shares tendered and the prices specified by the tendering stockholders. At the minimum price of $2.00 per share, Theragenics would repurchase a maximum of 5,000,000 shares, which represents approximately 14% of Theragenics’ outstanding common stock. Theragenics will fund this repurchase from available cash on hand. The low and high ends of the price range for the tender offer represent premiums of approximately 14% and 36%, respectively, to the closing price per share of $1.76 for Theragenics’ common stock on June 11, 2012, the last trading day prior to the announcement of the tender offer. The tender offer will be subject to various terms and conditions as will be described in offer materials that will be publicly filed and distributed to stockholders on or about June 12, 2012. Full Article
Theragenics gets buyout offer from investment firm; shares jump
- Medical device maker Theragenics Corp said it had received a takeover offer of $69.9 million to $71.4 million from Juniper Investment Co, representing a premium of 51-54 percent to its closing stock price on Friday.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
